Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
Paolo Tarantino, MD, discusses risk factors in early breast cancer, NCCN guideline-recommended therapies, and the transformative impact of HER2-targeted treatments over the past decade.
Video content above is prompted by the following:
- Discuss the risk factors and clinical characteristics that define high-risk early breast cancer, such as tumor size, nodal status, hormone receptor status, and residual disease after neoadjuvant therapy.
- How should clinicians approach risk stratification in early breast cancer to identify high-risk patients who may benefit from more aggressive treatment?
- Please provide a brief overview of treatment options in HER2+ breast cancer.
- Please highlight the NCCN guideline recommendations for managing early breast cancer, particularly Category 1 preferred options.
- How have the available HER2-targeted therapies changed the treatment landscape for patients with HER2+ breast cancer over the past decade or so?
- What are the key factors you consider when selecting an appropriate HER2-targeted therapy for your patients with HER2+ breast cancer?
- How do you approach the sequencing and combinations of HER2-targeted agents in the adjuvant, neoadjuvant, and metastatic settings?
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
